In the context of cancer, Tregs are recruited to the TME, where they suppress effector T cells and other immune cells through mechanisms such as secreting immunosuppressive cytokines (e.g., IL-10, TGF-β), expressing immune checkpoint molecules (e.g., CTLA-4, PD-1), and altering metabolic pathways. This evidence concerns the gene PDCD1 and cancer.